Design and tests of an HIV vaccine

British Medical Bulletin

Volumn 62, Issue 1, 2002, Pages 87-98

  McMichael, Andrew ^a   Mwau, Matilu ^a   Hanke, Tomas ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DNA VACCINE; GAG PROTEIN; GLYCOPROTEIN GP 120; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS INFECTION; VIRUS RECOMBINANT;

AIDS VACCINES; CLINICAL TRIALS, PHASE I; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; T-LYMPHOCYTE SUBSETS;

EID: 0036326909     PISSN: 00071420     EISSN: None     Source Type: Journal    
DOI: 10.1093/bmb/62.1.87     Document Type: Review

References (41)

1. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
2. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques
3. A vaccine for HIV type 1: The antibody perspective
4. HIV-1 neutralizing antibodies: How full is the bottle?
5. The antigenic structure of the HIV gp120 envelope glycoprotein
6. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
7. The challenge of viral reservoirs in HIV-1 infection
8. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1
9. Characterization of HIV-1-specific T-helper cells in acute and chronic infection
10. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T-cell receptor zeta chain
11. HIV-specific cytotoxic T lymphocytes in seropositive individuals
12. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma viral RNA load
13. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function
14. T cell responses and viral escape
15. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
16. + lymphocytes
17. Antivirally protective cytotoxic T cell memory to lymphocytic choriomeningitis virus is governed by persisting antigen
18. + lymphocytes, induced by infection with a vaccinia virus recombinant expressing the M2 protein of respiratory syncytial virus (RSV), correlates with resistance to RSV infection in mice
19. Protective cellular immunity: Cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization
20. + nef-specific cytotoxic T cells in vaccinated macaques
21. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus
22. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination
23. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
24. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants
25. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
26. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from CTL
27. Human immunodeficiency virus infection among high-risk seronegative prostitutes in Nairobi
28. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
29. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi
30. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from The Gambia
31. + responses
32. Antigen recognition by class I-restricted T lymphocytes
33. + T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
34. Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys
35. Design and construction of an experimental HIV-1 vaccine for a year 2000 clinical trial in Kenya
36. MVA vaccination against smallpox: Clinical tests with an attenuated live vaccinia virus strain (MVA) (author's translation)
37. Evolutionary and immunological implications of contemporary HIV-1 variation
38. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8
39. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen
40. + T cells during the primary immune response to Epstein-Barr virus in vivo
41. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine